Characteristic | n (%) |
Median age (range), years | 61.5 (27–88) |
Male | 56 (63) |
Caucasian | 85 (96) |
Disease stage | |
IIIB (unresectable) | 4 (4) |
IIIC (unresectable) | 6 (7) |
IV | 79 (89) |
M1a | 25 (28) |
M1b | 17 (19) |
M1c | 37 (42) |
LDH above ULN | 22 (25) |
ECOG 0 or 1 | 89 (100) |
Prior therapy | |
Radiation | 14 (16) |
Systemic* | 16 (18) |
*Includes BRAF and IL-1, but treatment with checkpoint inhibitor was not allowed per exclusion criteria.
BRAF, 8-rat proto-oncogene, serine/threonine kinase; ECOG, Eastern Cooperative Oncology Group; IL-1, interleukin-1; LDH, lactate dehydrogenase; ULN, upper limit of normal.